Metformin Use and Survival in Patients with Advanced Extrahepatic Cholangiocarcinoma: A Single-Center Cohort Study in Fuyang, China

Table 5

Complications during metformin use in the study group.

		Metformin used time	Survival time
		Median (IQR) (d)	Median (IQR) (d)
Tolerable	126	106.00 (80.50,160.75)	106.50 (80.50,163.00)
Active withdrawal due to intolerance	7	30.00 (14.00,60.00)	73.00 (32.00,95.00)
value		≤0.001	0.014